Lingfang Xia

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 1

Top Topics

Ejection Fraction

Squamous Cell Carcinoma

Prognostic Factors

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Lingfang Xia, Qi Zhou, Yunong Gao, Wenjing Hu, Ge Lou, Hong Sun, Jian Qing Zhu, Jin Shu, Xianfeng Zhou, Rong Sun, Xiaohua Wu
A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma. Nature communications 13 (1) (2022)